Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 451 to 475 of 903

TitleReference numberPublishedLast updated
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA692
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemiaTA694
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myelomaTA695
Acalabrutinib for treating chronic lymphocytic leukaemiaTA689
Avelumab for untreated metastatic Merkel cell carcinomaTA691
Avelumab for treating metastatic Merkel cell carcinomaTA517
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA687
Anakinra for treating Still's diseaseTA685
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)TA686
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic diseaseTA684
Erenumab for preventing migraineTA682
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myelomaTA680
Baricitinib for treating moderate to severe atopic dermatitisTA681
Dapagliflozin for treating chronic heart failure with reduced ejection fractionTA679
Filgotinib for treating moderate to severe rheumatoid arthritisTA676
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphomaTA677
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)TA678
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)TA674
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)TA675
Trabectedin for the treatment of advanced soft tissue sarcomaTA185
Mepolizumab for treating severe eosinophilic asthmaTA671
Brolucizumab for treating wet age-related macular degenerationTA672
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitorTA670
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancerTA668

Results per page

  1. 10
  2. 25
  3. 50
  4. All